Monday, March 21, 2016 | |||
9:00 am - 10:15 am | Plenary Session 1: Opening Ceremony Chair: Jean-Pierre Armand, Cancer Institute Gustave Roussy Chair: Giuseppe Giaccone, Georgetown University | ||
9:01 am - 9:08 am | Opening address Speaker: Giuseppe Giaccone, Georgetown University | ||
9:08 am - 9:15 am | Opening address Speaker: Louis Weiner, Georgetown University - LCCC | ||
9:15 am - 9:45 am | O1.1 TAT 2016 Honorary Award Lecture: Disrupting Early Clinical Trials Speaker: Anthony Tolcher, South Texas Accelerated Research Therapeutics | ||
9:45 am - 10:15 am | O1.2 Keynote lecture: Rational combinations of immunological, targeted and chemotherapeutic agents and the implementation of immunotherapy in targeted treatment strategies Speaker: Laurence Zitvogel, Cancer Institute Gustave Roussy | ||
10:15 am - 10:40 am | Break |
10:40 am - 12:00 pm | Plenary Session 2: Immuno-oncology (1) Chair: Michael Atkins, Geogetown-Lombardi Comprehensive Cancer Center Chair: Gail Eckhardt, University of Colorado Cancer Center |
10:41 am - 11:00 am | O2.1 Predictive biomarkers (positive and negative) for immunological agents Speaker: Janis Marie Taube, The Johns Hopkins Hospital |
11:00 am - 11:20 am | O2.2 Tumor genomics and response to immunotherapy Speaker: Matthew Hellmann, Memorial Sloan Kettering Cancer Center |
11:20 am - 11:40 am | O2.3 The microbiome and cancer therapy Speaker: Giorgio Trinchieri, National Cancer Institute |
11:40 am - 12:00 pm | General discussion |
12:00 pm - 1:00 pm | Lunch & Poster viewing |
1:00 pm - 2:30 pm | Plenary Session 3: Phase 1 Studies - Completed or in Progress (miscellaneous drugs & targets) Chair: Lesley Seymour, Queen's University Chair: Shivaani Kummar, Stanford University Cancer Institute |
1:01 pm - 1:15 pm | O3.1 A first in human study of the dual ROCK I/II inhibitor AT13148 in patients with solid tumours Speaker: Udai Banerji, The Institute of Cancer Research |
1:15 pm - 1:30 pm | O3.2 A Phase I/II and PK/PD Study of ASN002, a Potent Dual SYK/JAK Inhibitor, in Patients with Advanced Solid Tumors and B-Cell Lymphomas Speaker: Drew Rasco, South Texas Accelerated Research Therapeutics |
1:30 pm - 1:45 pm | O3.3 Phase I study of mTORC1/2 inhibitor BI 860585 as single agent or with exemestane or paclitaxel in patients with advanced solid tumors Speaker: Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori |
1:45 pm - 2:00 pm | O3.4 Dose escalation study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours Speaker: Christophe Massard, Cancer Institute Gustave Roussy |
2:00 pm - 2:15 pm | O3.5 A Phase 1a/b Study of OMP-131R10, an Anti-RSPO3 Antibody, in Advanced Solid Tumors and Previously Treated Metastatic Colorectal Cancer Speaker: Gail Eckhardt, University of Colorado Cancer Center |
2:15 pm - 2:30 pm | O3.6 A first-in-human first-in-class trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours Speaker: Ruth Plummer, Newcastle University |
2:30 pm - 2:55 pm | Break |
2:55 pm - 4:35 pm | Plenary Session 4: New Drugs and Targets in Hemato-Oncology Chair: Yves Pommier, National Cancer Institute Chair: Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori |
2:56 pm - 3:15 pm | O4.1 Targeting intracellular pathways in chronic lymphocytic leukemia Speaker: Jennifer Woyach, The Ohio State University |
3:15 pm - 3:35 pm | O4.2 Monoclonal antibody based strategies in acute leukemia: emphasis on bi-specific antibodies Speaker: Farhad Ravandi, The University of Texas MD Anderson Cancer Center |
3:35 pm - 3:55 pm | O4.3 Chimeric Antigen Receptor (CAR)-modified T cell therapy in hematologic malignancies Speaker: David L. Porter, University of Pennsylvania |
3:55 pm - 4:10 pm | General discussion |
4:10 pm - 4:40 pm | Keynote Lecture: Genomic analysis and targeted therapy of lung cancers Speaker: Matthew Meyerson, Dana-Farber Cancer Institute |
Special Sumposium (non-CME) |
4:45 pm - 5:45 pm | Special Symposium (non-CME) Immuno-Oncology and Third-Generation Tyrosine Kinase Inhibitors Company Updates Chair: Hilary Calvert, UCL Cancer Institute Chair: Jean-Pierre Armand, Cancer Institute Gustave Roussy |
4:46 pm - 5:00 pm | IMMUNE CHECKPOINT BLOCKADE CLINICAL THERAPY.. AND BEYOND Speaker: Suba Krishnan, Bristol-Myers Squibb |
5:00 pm - 5:15 pm | PERSONALIZED APPROACHES TO COMBINATION IMMUNOTHERAPY Speaker: Carol O’Hear, Genentech |
5:15 pm - 5:30 pm | MK-6018: A NOVEL IMMUNE CHECKPOINT INHIBITOR TARGETING CEACAM1 Speaker: Archie N. Tse, Merck & Co |
5:30 pm - 5:45 pm | BI 1482694: A THIRD GENERATION (MUTANT SPECIFIC) EGFR TKI Speaker: William F. Goeckeler, Boehringer Ingelheim Pharmaceuticals |
6:00 pm - 7:00 pm | Poster Viewing & Welcome Reception |